CellSource Co

CellSource Co Fixed Asset Turnover

The Fixed Asset Turnover of CellSource Co (4880.T) as of Oct 27, 2026 is 25.71. In the previous year, Fixed Asset Turnover was 26.57 — a change of -3.24% (lower).

Fixed Asset Turnover

25.71

YoY

-3.24%

Last updated:

Fixed Asset Turnover of CellSource Co is 2022 25.71 . Fixed Asset Turnover of CellSource Co was 2021 26.57 . It decreases by -3.24% lower compared to the previous year.

The CellSource Co Fixed Asset Turnover history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Fixed Asset Turnover
Date
Fixed Asset Turnover
Jan 1, 2017
21.63 JPY
Jan 1, 2018
28.20 JPY
Jan 1, 2019
22.08 JPY
Jan 1, 2020
22.63 JPY
Jan 1, 2021
26.57 JPY
Jan 1, 2022
25.71 JPY
The CellSource Co Fixed Asset Turnover history
YEARFixed Asset TurnoverYoY
25.71-3.24%
26.57+17.40%
22.63+2.50%
22.08-21.72%
28.20+30.40%
21.63—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CellSource Co Stock analysis

What does CellSource Co do? CellSource Co., Ltd. generates revenue through its Regenerative Medicine Related business segment, which provides contracted services for processing tissues and cells from fat and blood to medical institutions, along with support services for regenerative medicine laws and regulations related to safety assurance. The company also sells medical equipment within this segment. The Consumer business segment focuses on selling cosmetics and facial products directly to general consumers. Both segments operate under the company's brand without additional brand names mentioned in the description. The Regenerative Medicine Related business segment targets medical institutions and regulatory compliance support for regenerative medicine safety, while the Consumer business segment serves general consumers seeking cosmetics and facial care products. The company's products include processed tissue and cell services, regulatory support, medical equipment, and consumer skincare items, all sold under the CellSource brand. CellSource Co., Ltd. employs 109 full-time employees to manage its two business segments, with the Regenerative Medicine Related segment handling medical services and equipment sales, and the Consumer segment focusing on direct-to-consumer product sales. The company's revenue streams are derived from these two distinct operational areas without any additional external partnerships or third-party brands. CellSource Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CellSource Co stock

Fixed Asset Turnover of CellSource Co is 25.71 in 2022.

Fixed Asset Turnover of CellSource Co changed from 26.57 to 25.71, representing a -3.24% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Fixed Asset Turnover CellSource Co since 2006 – with annual values, charts, and detailed analysis.

Fixed asset turnover measures revenue generated per unit of PP&E. Higher ratios indicate more efficient utilization of physical assets.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Fixed Asset Turnover's CellSource Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Fixed Asset Turnover's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Fixed Asset Turnover.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — CellSource Co

All Key Metrics — CellSource Co